CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB005

Prostate Biopsy Specimen Analysis

Defines BCBSOK reimbursement and specimen handling criteria for pathological examination of prostate biopsy specimens used in diagnosis, staging, and management of prostate cancer; applies to providers submitting claims to Blue Cross and Blue Shield of Oklahoma.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy CPCPLAB005

Change TypeClarified / Revised / Added

Effective DateJan 15, 2025

Next Review Date

Key ActionSubmit documentation demonstrating 12-core extended sampling and specimen handling (one vial per sextant, max two cores per vial) to support reimbursement for pathological examination.

SourceLink

POLICY UPDATE CHANGES

Earlier (02/01/2024) revision added 'pathological examination of tissue obtained from a…' to all criteria and removed 3D mapping and several codes (0443T, 55700, 55706).

Added reimbursement statement permitting follow-up biopsy pathological examination (excluding saturation biopsy) when initial biopsy is negative but clinical suspicion persists.

Document updated with literature review; reimbursement information unchanged; references updated.

3reimbursement statements

2procedure codes listed

2025-01-15plan effective

Coverage Criteria

Reimbursement criteria

Covered when meeting the specific clinical scenarios below:

Initial diagnosis: Pathological examination of tissue obtained from a prostate biopsy involving 12 core extended sampling may be reimbursable in the initial diagnosis of prostate cancer after abnormal PSA, presence of a palpable nodule on digital rectal examination, or suspicious radiologic findings.12-core extended sampling; see specimen handling note

See Note 1: one vial per sextant, no more than two core samples per vial.

Follow-up biopsy after negative initial biopsy: Pathological examination of tissue from a follow-up prostate biopsy may be reimbursable when clinical suspicion for prostate cancer remains and the initial biopsy was negative; prostate saturation biopsy is excluded.Excludes prostate saturation biopsy

Saturation biopsies are not reimbursable for pathology per statement #3.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy CPCPLAB005

Change TypeClarified / Revised / Added

Effective DateJan 15, 2025

Next Review Date

Key ActionSubmit documentation demonstrating 12-core extended sampling and specimen handling (one vial per sextant, max two cores per vial) to support reimbursement for pathological examination.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Billing

Billing Rule

Reimbursement note: prostate biopsy pathology

Pathological examination of prostate biopsy tissue may be reimbursable for the initial diagnosis of prostate cancer when performed as follow‑up to abnormal PSA results, a palpable nodule on digital rectal examination, or suspicious radiologic findings. Reimbursement is limited to examinations of tissue obtained from a 12‑core extended sampling prostate biopsy (one vial per sextant, with no more than two core samples per vial).

Affected procedure: pathological examination of prostate biopsy tissue from 12‑core extended sampling
Specimen handling: one vial per sextant, ≤2 cores per vial

Billing Rule

Provider billing and coding responsibilities

Providers are responsible for submitting accurate documentation and coding claims using HIPAA‑approved code sets and industry standard coding guidelines. Use appropriate CPT, HCPCS, ICD‑10 and other standard code sets and follow CCI edits and CMS/NCCI guidance.

Documentation Required

Required documentation and specimen handling

Providers must submit complete and accurate documentation of services performed and ensure proper specimen labeling and handling for prostate biopsy samples. Code claims using valid HIPAA‑approved code sets and follow industry coding guidance. Upon request, providers should furnish additional clinical or pathology documentation to support medical necessity.

Code claims using CPT, HCPCS, ICD‑10, NDC as applicable
Specimen rule: one vial per sextant, no more than two cores per vial

Denial Risk

Claim review and potential denial triggers

Claims for pathological examination of prostate biopsy tissue are subject to claim review and code edit protocols. Reimbursement will be reviewed against plan benefits, provider contract language, applicable medical policies, clinical payment and coding policies, and coding software logic. Claims for prostate saturation biopsy pathological examination are not reimbursable for diagnosis, staging, or management of prostate cancer and may be denied.

Non‑reimbursable: pathological examination of tissue from prostate saturation biopsy
Claims may be denied if documentation or coding does not support medical necessity

Definitions

12‑core extended sampling — definition

Term12‑core extended sampling

DefinitionProstate biopsy protocol involving collection of 12 cores for initial diagnostic evaluation after abnormal PSA, palpable nodule, or suspicious imaging

Reimbursement contextPathological examination of tissue from 12‑core extended sampling may be reimbursable for initial diagnosis

Prostate saturation biopsy — definition and exclusion

TermProstate saturation biopsy (high‑core‑count mapping biopsy)

DefinitionHigh‑core‑count mapping biopsy (saturation biopsy) involving multiple cores beyond standard 12‑core sampling

Reimbursement stancePathological examination of tissue obtained from a prostate saturation biopsy is not reimbursable for diagnosis, staging, or management of prostate cancer

OpenPayer

Prostate Biopsy Specimen Analysis

Coverage Criteria

Coding and Specimen Handling

Provider Actions and Billing

Definitions

Background

88305
G0416